Eisai Co. Ltd.

In News

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen

Biogen - Jul 14, 2026

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation - Eisai

Eisai - Mar 17, 2026

Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026 - PR Newswire

PR Newswire - Jul 13, 2026

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters

Reuters - Jul 13, 2026

Eisai Co Ltd (4523) - MSN

MSN - Jul 11, 2026

Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com

Investing.com - Jul 14, 2026

Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease - marketscreener.com

marketscreener.com - Jul 12, 2026

Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease - Newswire Canada

Newswire Canada - Jul 16, 2026

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day - Slideshow (OTCMKTS:ESAIY) 2026-05-25 - Seeking Alpha

Seeking Alpha - May 25, 2026

Daily Brief Japan: Kawasaki Heavy Industries, Eisai Co Ltd, WingArc1st Inc, Nippon Paint Holdings, Curves Holdings Co Ltd, Create Sd Holdings Co, Migalo Holdings, Usen-Next Holdings Co Ltd, EJ Holdings Inc and more - Smartkarma

Smartkarma - Jul 15, 2026

Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026 - ACN Newswire

ACN Newswire - Jul 15, 2026

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease - Biogen

Biogen - Jul 13, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment